102 results about "Sphingomyelin" patented technology

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.

The present disclosure provides a liposomal system comprising an aqueous medium having dispersed therein liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the aqueous medium being in iso-osmotic equilibrium with said intraliposomal aqueous compartment, the liposomes having a membrane comprising a liposome forming lipids, at least one of which being sphingomyelin (SPM), the liposomal system having increased stability as compared to the same liposomes free of SPM, and in one embodiment being stable during long-term storage, said stability being characterized in that no more than 30% of the at least one active agent is present in the aqueous medium after said storage. Further provided by the present disclosure are a method for storage of liposomes making use of the liposomal system; use of the liposomal system for the treatment of a medical condition or for the diagnostic of a medical condition; a pharmaceutical or diagnostic composition comprising the liposomal system, and a method of treating or diagnosing of a medical condition comprising administering to a subject an amount of the liposomal system.

The invention discloses a diagnosis and / or typing marker for the PCOS (polycystic ovarian syndrome) and an application of the preparation reagent and particularly relates to an application of cyclic guanosine monophosphate, dehydroepiandrosterone sulfate, palm sphingomyelin combined HDL-C (high-density lipoprotein cholesterol) and the left follicle number as the diagnosis and / or typing marker for the PCOS. Compared with existing PCOS diagnosis clinical indexes, the marker can realize the effect of distinguishing a PCOS subgroup I and a PCOS subgroup II through combined diagnosis of cyclic guanosine monophosphate, dehydroepiandrosterone sulfate and palm sphingomyelin. In combination of combined diagnosis of HDL-C (high-density lipoprotein cholesterol) and the left follicle number, the very high diagnosis accuracy is realized for a normal group, the PCOS subgroup I and the PCOS subgroup II, and accurate and effective index systems are provided for clinical disease diagnosis.

The invention discloses a brain targeting liposome and the process for preparing brain targeting liposome pharmaceutical preparation, wherein the brain targeting liposome pharmaceutical preparation comprises medicament, various synthesized or natural phosphatide with brain targeting function as liposome coating material, cephalin having brain tissue absorption accelerating agent, liposome coating material, sphingomyelin with brain tropism and immunity activation, cholestrin for liposome coating material and liposome stabilizing agent, vitamin E as anti-oxidizing agent and polyoxyethylene glycols and phosphatide derivative for extending the half-decay time of liposome pharmaceutical blood.

The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1 / 0:0 / 0:0) and sphingomyelin (d18:2 / 16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

The present invention is based on the idea of determining certain molecular lipids from a subject's blood sample, for example from serum or plasma sample, and based on the amounts of the determined lipids determining the amount of liver fat and / or diagnosing NAFLD in the subject. More specifically the subjects with elevated liver fat amount and NAFLD are characterized by elevated triglycerides with low carbon number and double bond content in the blood sample. Lysophosphatidylcholines, ether phospholipids, sphingomyelins and PUFA-containing phospholipids are diminished in the blood samples of subjects with an elevated liver fat amount and NAFLD. The method of the present invention can be further used for monitoring the subject's response to the treatment of NAFLD or to the treatment of lowering of the liver fat amount in the subject.

The present disclosure provides a composition and method for promoting functional neuronal development in pediatric subjects. The composition comprises in some embodiments up to about 7 g / 100 Kcal of a fat or lipid source; up to about 5 g / 100 Kcal of a protein source; about 3 mg / 100 Kcal to about 50 mg / 100 Kcal of phosphatidylethanolamine; about 0.15 mg / 100 Kcal to about 75 mg / 100 Kcal of sphingomyelin; and about 5 mg / 100 Kcal to about 75 mg / 100 Kcal of docosahexaenoic acid. The methods comprise, in some embodiments, administering the aforementioned composition to a pediatric subject.

An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.

The invention provides a serum metabolism marker for diagnosis of gestational diabetes mellitus and application of the serum metabolism marker. Specifically, sphingomyelin SM (8:0; 2O / 11:0) and oleoyl carnitine CAR (18:2) can serve as a biomarker of gestational diabetes mellitus, can be used for evaluating the disease risk of the gestational diabetes mellitus or diagnosing the gestational diabetes mellitus, and have the advantages of high accuracy and strong sensitivity, so that that the serum metabolism marker has an important clinical application value.

Provided, among other things, is a delivery composition comprising: an aqueous carrier; a lipid component suspended in the carrier comprising significant amounts of type A lipid, fatty acid, and bilayer-stabilizing steroid(s), wherein type A lipid is one or more of any of phospholipid, ceramide(s) sphingomyelin(s) and glucocerebroside(s); and a bioactive agent, wherein (a) the delivery composition is packaged with a label with directions for mucosal, pulmonary or oral administration, and / or (b)(i) the viscosity of the composition is adjusted to a viscosity appropriate for spraying and / or (ii) the type A lipid comprises conjugate(s) of lipid-phase anchoring hydrophobic moieties and flexible, soluble polymers, and / or (iii) comprises a stabilizing effective amount of soluble polymers.

The present invention provides a method for long-term stabilization of inositol dehydrogenase, ketoamine oxidase and sphingomyelinase in liquid. The method is used to prepare an enzymatic biochemicalkit for determining inositol, glycated albumin and small and dense low density lipoprotein cholesterol for a purpose of enabling the enzymatic biochemical kit to have a shelf life of 12 months or more. The method is characterized in that a composition of 4-formylbenzeneboronic acid and benzyldimethylphenol polyoxyethylene ether is added to a reagent solution for preserving enzymes, and concentrations of the 4-formylbenzeneboronic acid and benzyldimethylphenol polyoxyethylene ether are preferably 0.008-0.012 w / V% and 0.1-0.2 w / V%, respectively.

Using NMR / MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and / or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker.

Compositions and methods relating to modulating thermogenic regulation are disclosed. The compositions and methods can be used to treat diseases or conditions such as obesity or cardiometabolic disorders such as type 2 diabetes mellitus, NAFLD and NASH. Compositions include an adipocyte-targeting composition that includes a therapeutic agent capable of modulating thermogenic regulation, a targeting element facilitating cellular uptake and delivery of the therapeutic agent to a targeted adipocyte, and liposomal particles comprising sphingomyelin, DMPC, and cholesterol, wherein the liposomal particles enhance intra-cellular penetration of the therapeutic agent and protect the therapeutic agent from degradation.

The invention provides a detection reagent kit optimized based on modified sphingomyelinase by an HDL3 color comparison method. The detection reagent kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises Tris-HCl, PEG6000, BSA, Polyoxyethylene styrenated phenyl ether derivative and the like, and the reagent R2 comprises Tris-HCl, PEG6000, mPEG-SMASE2, Polyoxyethylene polycyclic phenyl ether. The invention further provides a preparation and utilization method of the detection reagent kit optimized based on modified sphingomyelinase by the HDL3 color comparison method. The reagent kit can be used for analysis of a full-automatic biochemical analyser, is low in cost and high in automation, and can greatly save the detection time. Compared with like products, the reagent kit disclosed by the invention is higher in stability and sensitivity.

The invention discloses sheath fluid for a urine analyzer and a preparation method thereof, which belong to the technical field of sheath fluid. The technical problem that sheath fluid for a urine analyzer in the prior art contains an organic solvent and needs to be heated and dissolved is solved. The sheath fluid for the urine analyzer comprises water, an osmotic pressure compensating agent, a chelating agent, a surfactant, a particle stabilizer and an antibacterial agent, the pH range is 6-8, and the osmotic pressure range is 220-340 mOsm / kg; the particle stabilizer is one or more of sodiumhyaluronate, sphingomyelin, adenine, aprotinin, trehalose, glucose and the like, and in the sheath fluid, the mass concentration of the particle stabilizer is less than or equal to 4g / L. The sheath fluid for the urine analyzer can form sheath flow without changing the particle form, the corrosion to a detection device is small, and a sample wrapped by the sheath fluid not only enables the detection device to count particles, but also can be shot and imaged at a high speed.

The embodiment of the invention relates to infant formula milk powder rich in a milk fat globule membrane protein, phospholipid and oligosaccharide. The infant formula milk powder takes raw milk as araw material, and through formula adjustment, the content of bioactive substance MFGM-protein with special functional components, lactoferrin(LF), alpha-lactalbumin (alpha-La), total galactooligosaccharides(GOS), total polyfructose, sialic acid, total phospholipids, sphingomyelin(SM), lecithin (PC), phosphatidylserine(PS), phosphatidylethanolamine(PE), phosphatidylinositol(PI), ganglioside(Gang),triglyceride(TAG) and diglyceride( DAG ), is increased, the purpose of promoting field planting of probiotics in intestines flora of babies, particularly notably enriching lactic acid bacteria in intestines, reducing infectious microbes of unsorted bacteria families, increasing the content of immunological factors in the intestines and reducing the incidence rate of intestines diseases can be realized. The formula is suitable for development of formula milk powder for infants and large infants.

A method, and associated kit, for assaying the activity of lysosomal enzymes present in dried bodily fluids and cell tissue samples, such as α-L-iduronidase, β-D-galactosidase, β-D-glucosidase, chitotriosidase, total α-D-galactosidase and α-D-galactosidase A, hexosaminidase A and B, α-D-mannosidase, β-D-mannosidase, α-L-fucosidase, N-acetyl-α-galactosaminidase, arylsulfatases, sphingomyelinase, β-galactocerebrosidase, iduronate-2-sulfatase and β-D-glucuronidase. The method includes: (a) combining with a dried bodily fluid or cell tissue sample containing at least one type of lysosomal enzyme: (1) an eluent, (2) an incubation buffer and (3) a substrate or substrates capable of reacting with the assayed lysosomal enzymes and producing their corresponding enzyme product or products, (b) allowing the dried bodily fluid or cell tissue sample to react with the eluent, incubation buffer and substrate or substrates for an adequate time and temperature, and (c) applying measuring means to the enzyme product to determine the activities of the lysosomal enzymes present.

The invention discloses a freeze-drying protective agent for sphingomyelinase and a preparation method, and belongs to the technical field of biology. The freeze-drying protective agent of sphingomyelinase comprises the following components: 0.2%-0.3% (w / v) of cane sugar, 0.1%-0.4% (w / v) of trehalose, 0.2%-0.5% (w / v) of D-mannitol, 0.1%-0.4% (w / v) of glycine, 0.02%-0.05% (v / v) of Tween 20 and 5-10 mM of Mg<2+>. Through formula screening and optimization, the obtained sphingomyelinase freeze-dried powder has the characteristics of high enzyme activity, good thermal stability, long storage time and good appearance.

A nutritional composition having a total energy content of 67 kcal / 100 ml or lower and including: a protein content which is 1.25 g / 100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg / 100 ml, a cholesterol content of 5-10 mg / 100 ml, and a sphingomyelin content of 9-15 mg / 100 ml is disclosed.

The present invention relates to the technical field of cosmetics, in particular to a liposome structure, composition and preparation method for skin cleaning and anti-aging, which consists of two liposomes A and B with different structures in a weight ratio of 1:1; Wherein, the liposome A is a multilayer liposome structure, which is formed by wrapping the skin cleansing composition with a wall material, and the composition of the liposome A wall material is lecithin and soybean lecithin; the liposome B is a single-layer liposome The lipid vesicle structure is formed by wrapping the skin anti-aging composition with the wall material, and the components of the liposome B wall material are sphingomyelin, cholesterol, fatty acid, phosphatidylcholine and cholesterol sulfate. The present invention adopts liposome A and microliposome B with two different particle sizes and structures to wrap the skin cleansing composition and the skin anti-aging composition respectively, and acts on the skin surface and deep layer of the skin respectively. The mutual synergy and mutual promotion can achieve significant skin cleansing and anti-aging effects.

An agent for preventing infection of influenza virus or a food and drink for preventing infection of influenza virus is provided. The agent for preventing infection of influenza virus and food and drink for preventing infection of influenza virus containing a fat globule membrane component as an active ingredient. The agent for preventing infection of influenza virus and food and drink for preventing infection of influenza virus containing a phospholipid with sphingosine and / or a derivative thereof, particularly sphingomyelin as an active ingredient.

The invention provides a biomarker for diagnosing the working of nervonic acid supplemented for ischemic hypoxic encephalopathy and application of the biomarker. The biomarker comprises ceramide phosphate (d18: 1 / 24: 1(15Z)), and the ceramide phosphate is combined with any one selected from sphingomyelin (d18: 1 / 15: 0), docosapentaenoic acid, hexanoyl carnitine, phosphatidylcholine (22: 6( / 20: 5) or 2-hydroxyhexadecanoylcarnitine to diagnose whether the nervonic acid supplemented for the ischemic-hypoxic encephalopathy takes effect or not. According to the biomarker for diagnosing the working of nervonic acid supplemented for ischemic hypoxic encephalopathy, by detecting the biomarker, whether nervonic acid is absorbed and transformed by a body suffering from the ischemic hypoxic encephalopathy or not can be judged, and guiding significance is provided for judging whether acer truncatum bunge nervonic acid oil or similar products have effects or not when the acer truncatum bunge nervonic acid oil or similar products are taken by patients with the ischemic hypoxic encephalopathy.

Use of an α-lactalbumin enriched whey protein extract as a source of sphingomyelin in a synthetic nutritional composition for an infant or child wherein, the α-lactalbumin enriched WPE is obtained by a process comprising: a. acidifying a whey protein product to pH 4 or below b. forming a low calcium whey protein product by concentrating the proteins in the acidified whey protein until the calcium to protein ratio is less than about 0.001 and, c. Precipitating α-lactalbumin from the low-calcium whey protein product, wherein said precipitating step includes the sub-steps of: I. diluting the low-calcium whey protein product, II. adjusting the pH of the diluted low-calcium whey protein product to between 4 and 5 to form a precipitate and soluble proteins, and III. Separating the precipitate proteins from the soluble proteins.

The invention relates to a hydrothorax exosome metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. The hydrothorax exosome metabolite combination for diagnosing the tuberculous pleurisy is prepared from dimethylglycine, choline, acyl carnitine with the ratio of 10: 2, phosphatidylcholine with the ratio of 35: 6, phosphatidylcholine o with the ratio of -36: 0, phosphatidylethanolamine with the ratio of 33: 2, sphingomyelin with the ratio of 28: 1 and oleic acid. The kit for diagnosing the tuberculous pleurisy comprises an internal standard substance required for detecting the concentration of the metabolites in the hydrothorax exosome sample extraction solution. A combined marker provided by the invention has the characteristics of high sensitivity and high specificity for the diagnosis of tuberculous pleurisy, and meanwhile, can be complementary with the traditional marker adenosine deaminase, and can be used for the auxiliary diagnosis of the tuberculous pleurisy by being combined with the traditional marker adenosine deaminase.

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition, in which liposomes encapsulate a drug, with a platinum preparation. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) a platinum preparation, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin; and cholesterols, the liposome composition includes a drug and has an inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the platinum preparation are administered simultaneously or sequentially.

Novel cyclic and acyclic oxazaphospholanes are described, as well as their use in the synthesis of sphingomyelin and sphingomyelin analogous. The production of synthetic sphingomyelins is also described. 2S, 3R stereoisomers of oxazaphospholanes and sphingomyelins, and synthetic methods for their preparation are described.